中国耐药皮肤癣菌感染诊治与防控专家共识(2024版)  

Expert consensus on the diagnosis,treatment,prevention and control of antifungal-resistant dermatophyte infections in China(2024)

作　　者：中国中西医结合学会皮肤性病学分会真菌学组 中国耐药皮肤癣菌病诊治与防控工作组 刘维达 Mycology Group,Combination of Traditional and Western Medicine Dermatology;Chinese Antifungal-Resistant Dermatophytosis Expert Consensus Group;Liu Weida

机构地区：[1]不详

出　　处：《中华皮肤科杂志》2024年第5期418-425,共8页Chinese Journal of Dermatology

基　　金：国家重点研发计划项目(2022YFC2504800、2022YFC3601800)。

摘　　要：耐药皮肤癣菌感染是近期临床微生物领域与皮肤病领域关注的热点。我国已经出现耐药皮肤癣菌感染病例,预示存在人群传播的风险。中国中西医结合学会皮肤性病学分会真菌学组、中国耐药皮肤癣菌病诊治与防控工作组组织专家基于已有的循证医学证据和研究数据,对耐药皮肤癣菌的病原学、流行病学、菌株鉴定、体外药物敏感性试验以及耐药皮肤癣菌感染的诊断、治疗和防控提出推荐建议,制订了完整的诊治方案,以期为我国耐药皮肤癣菌感染的临床诊治与防控提供科学参考。Drug-resistant dermatophyte infections are a hotspot issue in the fields of clinical microbiology and dermatology.Cases of antifungal-resistant dermatophyte infections have emerged in China,predicting a risk of transmission among humans.Based on the existing medical evidence and research data,the Mycology Group of Combination of Traditional and Western Medicine Dermatology and Chinese Antifungal-Resistant Dermatophytosis Expert Consensus Group organized experts to make recommendations and develop the consensus on the pathogenicity,epidemiology,identification,in vitro drug susceptibility test of antifungal resistance dermatophytes,and the diagnosis,treatment,prevention and control of the infections.Further,complete diagnosis and treatment recommendations were made in the consensus,aiming to provide a scientific reference for the clinical diagnosis,treatment,prevention and control of drug-resistant dermatophyte infections in China.

关 键 词：皮肤真菌病 皮肤癣菌 真菌耐药 印度毛癣菌 诊断 治疗 防控 

分 类 号：R519[医药卫生—内科学]